An der Goldgrube 12
BioNTech AG is Europe’s largest privately held biopharmaceutical company pioneering the development of individualized therapies for cancer and other diseases.
Founders: Ugur Sahin and Christoph Huber
Founder and CEO: Ugur Sahin
COO: Sean Marett
CFO: Sierk Poetting
51 articles with BioNTech
BioNTech SE announced the pricing of its initial public offering of 10,000,000 American Depositary Shares representing 10,000,000 ordinary shares at a public offering price of $15.00 per ADS, for gross proceeds of $150,000,000.
BioNTech SE announced that it has filed a registration statement on Form F-1 with the United States Securities and Exchange Commission to offer 13,200,000 American Depositary Shares representing its ordinary shares to the public.
Bill & Melinda Gates Foundation invests $55 million in an infectious disease collaboration that could reach up to $100 million in total funding
BioNTech Raises USD 325 Million in an Upsized Series B Financing to Further Advance Individualized Immuno-Oncology Pipeline
One of the largest private EU biotech funding events expands global shareholder base
This makes it one of the biggest single private funding rounds for a biotechnology company in European history.
Pancreatitis is an inflammation of the pancreas that accounts for 275,000 hospitalizations in the United States annually.
6/20/2019Biotech and pharma companies from across Europe and Asia share company and pipeline updates.
BioNTech and Genmab Initiate First-In-Human Phase I/IIa Trial of Bispecific Antibody DuoBody®-PD-L1x4-1BB in Solid Tumors
BioNTech SE, a clinical-stage biotechnology company focused on patient-specific immunotherapies for the treatment of cancer and other serious diseases, announced that the first-in-human Phase I/IIa study with DuoBody-PD-L1x4-1BB has been initiated.
Companies from across the globe provide updates to their pipelines and businesses, with news from BioNTech, Mologic, Akcea, RedHill, and more.
Four biotech companies began trading on the Nasdaq this morning. Here's a look at today’s launches and one rumored IPO.
BioNTech SE announced the acquisition of antibody assets and infrastructure from San Diego-based MabVax Therapeutics Holding, Inc., a clinical-stage oncology drug development company.
In addition to the planned BioNTech IPO, many other pharma and biotech companies in Europe, Asia and elsewhere shared news for the week.
For BioNTech, the IPO will follow a funding round that brought about $270 million into the coffers of the privately-held company.
Biotech and pharma companies from across the globe share data and news in a weekly roundup.
Messenger RNA (mRNA) is a family of RNA molecules that transport genetic information from DNA to the ribosome, where it specifies the amino acid sequence that creates proteins. In theory, by coding your own mRNA, it should be possible to insert it into the cells and turn them into protein factori...
BioNTech AG and MAB Discovery GmbH announced that both partners have entered into a definitive agreement under which BioNTech will acquire MAB Discovery’s operational antibody generation unit.
BioNTech AG inked a deal with Munich, Germany’s MAB Discovery GmbH to acquire MAB’s operational antibody generation unit. No financial details were disclosed.
Days ahead of the J.P. Morgan Healthcare Conference, Germany-based BioNTech extended its three-year-old collaboration with Sanofi as the companies look to co-develop the first cancer immunotherapy candidate for solid tumors.
BioNTech: MammaTyper® Validated as Predictor for Response After Neoadjuvant Chemotherapy (NACT) in Patients with Early Breast Cancer (BC)
New results from a clinical performance evaluation study of the CE-marked IVD MammaTyper® which were presented at the European Society for Medical Oncology (ESMO) in Munich in October.(1,2)
BioNTech and the University of Pennsylvania Enter into Strategic Research Collaboration to Develop mRNA Vaccine Candidates Against Various Infectious Diseases
New research program between BioNTech and the University of Pennsylvania